Cancer

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,…

9 months ago

Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk…

9 months ago

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers

LEXINGTON, KY / ACCESSWIRE / March 5, 2024 / NX Development Corp. (NXDC) has achieved another milestone as we proudly…

9 months ago

Cantargia Reports New Preclinical Data on Antitumor Effects of Nadunolimab in Pancreatic Cancer

LUND, SE / ACCESSWIRE / March 5, 2024 / Cantargia (STO:CANTA) (Cantargia AB);(Nasdaq Stockholm: CANTA) today reported new preclinical data…

9 months ago

LinusBio Named “Fierce 15” Company of 2023 by Fierce Medtech

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list…

9 months ago

Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing

Results From a Large-Scale Prospective Study Investigating Long-Term Anti-Estrogen Therapy Recommendations Published in JNCCN — Journal of the National Comprehensive…

9 months ago

HealthJoy Releases Insights From 2024 Member Health Goals Report

Sixty Percent of Surveyed Members Identified They Are Managing an Ongoing Health ConditionCHICAGO, IL / ACCESSWIRE / March 5, 2024…

9 months ago

Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area

NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Gilead SciencesOriginally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.comMuch has…

9 months ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected…

9 months ago

New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure

Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness SurveyLAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies…

9 months ago